Cephalon appoints new CEO
FRAZER, Pa. — Cephalon on Thursday appointed Kevin Buchi as CEO and a member of the company’s board.
The board will address the role of company chairman in the future, Cephalon stated in a press release. William Egan will continue to serve as Cephalon’s independent presiding director.
"Kevin is an experienced pharmaceutical executive who has been involved in every aspect of running our business," Egan stated. "Over the course of many years, Kevin worked closely with Frank Baldino Jr. to create the company that we know today, and he has the passion, leadership skills, organizational abilities and unwavering commitment to patients that are critical to ensuring Cephalon’s continued growth and success."
Buchi, who has been with Cephalon for almost 20 years, had assumed day-to-day chief executive responsibilities for the company in August 2010. He previously served as a member of the Cephalon executive management team in the roles of COO and CFO. Additionally, for the last seven years, he has led the business development function with responsibility for mergers, acquisitions and in-licensing of products.
"Cephalon is an extraordinary company with one of the most robust pipelines in the industry focused on patients suffering from rare disorders and diseases for which there are no cures,” Buchi said. “We have expanded our global footprint dramatically in the last few years. I am confident that our diverse product portfolio, rich pipeline and global presence position us well for long-term growth and success."
Walgreens drives accelerating renewal program to big profit gains in record-setting first quarter
WHAT IT MEANS AND WHY IT’S IMPORTANT — Everyone likes to be proven right. And Walgreens’ leaders are justifiably proud of the company’s record performance in first quarter fiscal 2011.
(THE NEWS: Walgreens drives accelerating renewal program. For the full story, click here)
Two years after launching a sweeping, top-to-bottom realignment of its management, its retail mission, its cost structure and its merchandising and marketing strategy, Walgreens rode its retooled business to a profit bonanza. Net earnings in the quarter ended Nov. 30 jumped nearly 19%, to $580 million, over the same three-month period last year. On a per-share basis, net income jumped 26.5% to 62 cents per diluted share. Sales also hit a record, rising 6% to $17.3 billion.
All this in the face of a still-weak economy, the continuing integration of the 257-store Duane Reade drug store operation that Walgreens bought last spring and a huge ongoing store remodeling effort as the chain converts its thousands of stores nationwide to its Customer Centric Retailing format.
Dow Jones called the earnings gain “much bigger than expected,” and cited a consensus estimate by analysts polled by Thompson Reuters forecasting that the company would earn 54 cents a share. Walgreens beat that estimate handily.
Also a factor in the solid profit performance: the company’s aggressive stock-repurchase plan, which it said added four cents a share to the bottom line in the first quarter. In that three-month period alone, Walgreens bought back another $510 million of its own stock.
As has been the case for many years, the engine pulling the train is the pharmacy, which now accounts for nearly two-thirds (65.8%) of sales. There’s always a risk in putting so many eggs in one basket, but Walgreens’ heavy reliance on its prescription business has, more often than not, paid big dividends through good times and bad. And being the nation’s biggest pharmacy provider — the company said it now has 19.7% of the nation’s total retail prescription business — is not a bad place to be in an aging America.
The first-quarter performance offers solid evidence that the company’s decision in 2008 to shift more of its retail focus and its resources to health, wellness and disease prevention — and away from store expansion — has been fundamentally sound.
In a time of 70 million aging baby boomers moving into their peak prescription-using years, and a time of a healthcare system in dire need of new solutions as it grapples with an unsustainable cost model, Walgreens wisely has repositioned itself as a solution. And with the nation’s largest private flu shot program, along with 8,133 “points of care” — including 7,529 drugstore pharmacies, 122 on-site hospital pharmacies, home care centers, specialty pharmacies and hundreds of in-store clinics and worksite health centers — the pharmacy and healthcare giant offers some pretty convincing numbers as it markets itself to employers and government health plans as a lower-cost, patient-accessible alternative to steadily rising healthcare costs.
Improving medication adherence is critical
WHAT IT MEANS AND WHY IT’S IMPORTANT — The CVS Caremark-sponsored study that illustrates pharmacists and nurses are the most effective healthcare "voice" in promoting medication adherence among patients is important because it marks the first step toward unlocking the potential of the collaborative care model (i.e., pharmacists and nurses), and getting those people who matter to pay attention.
(THE NEWS: Adherence is boosted by face-to-face contact, study finds. For the full story, click here)
The reality is that this message comes at a critical time. As the clock ticks away toward full implementation of the Affordable Care Act in 2014, and with Republicans in the new Congress determined to repeal or at least replace the parts of it they don’t like — even if they can’t — there is going to be a greater focus on how all this extra health care is going to get paid for and what America is getting for its money.
As Troyen Brennan, EVP and chief medical officer of CVS Caremark and author of both reviews, stated, "These findings offer payers, healthcare providers and policy-makers guidance about how to develop programs that improve patient adherence. We know that pharmacists and nurses are among the most trusted healthcare professionals. This study shows that trust translates into effective patient communications."
Improving medication adherence is critical, and fixing it would mean closing a significant financial drain on the U.S. healthcare system. Nonadherence to medications costs the healthcare system up to $290 billion — yes, billion — a year because many of the hospitalizations can be avoided if patients take their medications as prescribed.